未知生产厂商
VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.
VGV-1 is appears to work through a mechanism that involves the use of the immune system, rather than attacking the virus itself. VGV-1 also has minimal side effects and is projected to be cost-effective. Because a treatment cycle with VGV-1 consists of just 16 injections, it is substantially less expensive than ART or HAART which require that drugs be taken once a day, or even more frequently.
Investigated for use/treatment in HIV infection.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
